COVIDH TECHNOLOGIES LIMITED

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) has announced its 34th Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 3:00 PM IST via video conference. The company will submit its Annual Report for the financial year 2025-26 and the Notice convening the AGM. The Annual Report and Notice are being sent electronically to members registered by August 28, 2026. Remote e-voting will be open from September 26 to September 28, 2026. MUFG Intime India Pvt. Ltd. has been engaged for the e-voting procedure. The Annual Report and Notice are available on the company's website and MUFG's website.

iSERA Lifesciences Ltd has announced its 34th Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 3:00 P.M. (IST) via video conference (VC) and other audio-visual means (OAVM). The meeting will comply with the Companies Act, 2013, and SEBI Listing Regulations. The notice and annual report for the financial year 2025-2026 are being sent electronically to members registered by August 28, 2026. E-voting will be available from September 26 to September 28, 2026. Key agenda items include adopting the audited financial statements for the year ended March 31, 2026, and appointing a director retiring by rotation.

iSERA Lifesciences Ltd announced that its Board of Directors met on September 1, 2026. The board approved the notice for the 34th Annual General Meeting (AGM) for FY 2025-26, scheduled for September 29, 2026. The AGM will consider and adopt the audited standalone financial statements for the year ended March 31, 2026, along with the Directors' and Auditors' reports. The Annual Report for FY 2025-26 and the appointment of M/s. Anuj Gupta & Associates as Scrutinizer for the AGM were also approved.

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its Rights Issue. The report, issued by Infomerics Valuation and Rating Private Limited, confirms no deviation from the objects for which the funds were raised. The Rights Issue aggregated to ₹8.08 crore. The company and the monitoring agency have declared that the report provides an objective view of the utilization of funds.

iSERA Lifesciences Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026. The Board of Directors met on August 7, 2026, to approve these results and the accompanying limited review report from the independent auditor. The company operates in a single segment, IT/ITES, as per Ind AS-108.

iSERA Lifesciences Ltd (formerly Covidh Technologies Limited) announced that its Board of Directors met on August 7, 2026. The board approved the un-audited standalone financial results for the quarter ended June 30, 2026, along with the independent auditor's limited review report. The company operates in the IT/ITES business segment.

iSERA Lifesciences Ltd has announced that its Board of Directors will convene on August 7, 2026. The primary agenda item for this meeting is to consider and approve the company's Unaudited Financial Results for the quarter ending June 30, 2026. Additionally, the company has informed that the trading window for its equity shares will be closed for designated persons from July 1, 2026, until 48 hours after the results are publicly disclosed. The notice regarding this meeting and trading window closure is available on the company's website and the BSE India website.

iSERA Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI regulations and the company's code of conduct. The window will be shut from July 01, 2026, until 48 hours after the announcement of the Un-Audited Financial Results for the Quarter ended June 30, 2026. The exact date of the board meeting to approve these results will be communicated later. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Covidh Technologies Limited announced its name change to iSERA Lifesciences Limited, effective June 16, 2026. The company's scrip ID on BSE will also change from 'COVIDH' to 'ISERA'. This rebranding aligns with the company's strategic shift towards the life sciences, pharmaceutical, biotechnology, and allied healthcare sectors. The Board also approved a new corporate logo reflecting this new identity. The company addressed a prior non-compliance with SEBI LODR Regulations regarding the name change application and has taken corrective steps, including shareholder ratification at an upcoming general meeting. Management has been directed to ensure future regulatory compliance.

Covidh Technologies Ltd, now known as iSERA Lifesciences Limited, declares that Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company. As of March 31, 2026, the company's paid-up equity share capital and net worth are less than ₹10 Crore and ₹25 Crore respectively, meeting the exemption criteria under Regulation 15(2) of SEBI (LODR) Regulations, 2015.